PLI Scheme for Bulk Drugs for Resilient Pharmaceutical Supply Chain

1. At a Glance

• The PLI Scheme for Bulk Drugs (Department of Pharmaceuticals) gives production-linked incentives for greenfield plants making critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs). The aim is lower import dependence and a more resilient pharma supply chain. [1]
• Outlay is ₹6,940 crore over 2020-21 to 2029-30, covering 41 products. [2]
• Five greenfield projects have now been commissioned. They cover Penicillin G, Clavulanic Acid, Sulfadiazine, Telmisartan, Olmesartan, PAP (a Paracetamol starting material) and Atorvastatin. [1]
• UPSC relevance: this is a case study in import substitution, health security, backward integration and strategic dependence on China (the China link is background knowledge, not from S1). It fits GS-III (industry, manufacturing) and GS-II (health).

2. Why in the News

• PIB (25 Sep 2026) highlighted five commissioned greenfield projects under the scheme. [1]
• Penicillin G manufacturing was restored in India after a gap of about three decades. [1]
• Kinvan's Nalagarh plant is India's first fermentation-based Potassium Clavulanate facility. [1]

3. Background & Evolution

• Rationale: reduce dependence on imported KSMs/DIs/APIs and build supply-chain resilience. [1]
• Cabinet approval came in 2020. [3] The exact month is not confirmed in retrieved text.
• Scheme period: 2020-21 to 2029-30. [2]
• Selection: 32 companies were chosen, with 48 projects for 33 APIs/DIs/KSMs. [2]
• Committed investment was ₹3,938.5 crore. Actual cumulative investment reached ₹4,709 crore. [2]
• Cumulative sales are ₹1,962 crore from FY2022-23, including exports of ₹479 crore. Imports avoided are ₹1,483 crore. [2]
• Related initiatives (Bulk Drug Parks scheme, PLI for pharmaceuticals) are from background knowledge and not verified against the retrieved sources.

4. Core Static Facts

Commissioned projects [1]:

• Lyfius Pharma (Aurobindo subsidiary): Penicillin G, Kakinada SEZ, Andhra Pradesh. Investment ₹2,270.05 crore, capacity 15,000 MT per annum, 2,353 direct jobs, over 90% domestic value addition.
• Kinvan Pvt Ltd (DPB Group): Clavulanic Acid, Nalagarh, Himachal Pradesh. Investment ₹504.68 crore, capacity 400 MT per annum, 465 jobs.
• Andhra Organics (Virchow subsidiary): Sulfadiazine, Telmisartan and Olmesartan, Pydibhimavaram, Srikakulam, Andhra Pradesh. Investment ₹151.47 crore, 221 jobs. Sulfadiazine imports are down about 73% against the FY2019-20 baseline.
• Meghmani LLP: Para Amino Phenol (PAP), Dahej, Gujarat. Investment ₹60.46 crore, capacity 13,500 MT per annum.
• Centrient Pharmaceuticals: Atorvastatin, Nawanshahr, Punjab. Investment ₹161.13 crore, capacity 206 MT per annum, over 80% domestic value addition.

Terminology:

• Penicillin G is a fermentation-based KSM. It is used to make the intermediate 6-APA, which goes into amoxicillin and ampicillin. [1]
• Clavulanic Acid is a β-lactamase inhibitor. [1]

5. Multi-Dimensional Analysis

Economic

• Investment exceeded commitments (₹4,709 crore against ₹3,938.5 crore). [2]
• Import substitution and exports: ₹1,483 crore of imports avoided and ₹479 crore exported. [2]
• Employment: 2,353 direct jobs at the Penicillin G plant alone. [1]

Strategic / Health Security

• Penicillin G addressed a "strategically concentrated vulnerability" in the antibiotic supply chain. It reduces exposure to supply disruptions and price spikes. [1]

Scientific / Technological

• The projects span fermentation-based (Penicillin G, Clavulanic Acid) and chemically synthesised inputs. [1]
• Andhra Organics developed its technology in-house. [1]

Administrative / Regional

• Plants are spread across Andhra Pradesh, Himachal Pradesh, Gujarat and Punjab. [1]
• Himachal Pradesh is described as a "hill State", which adds to its pharma manufacturing base. [1]

Governance

• Incentives are disbursed only against production. The scheme's ceiling is about ₹6,000 crore against the ₹6,940 crore outlay. [2]

6. Recent Developments (last 12-18 months)

• 25 Sep 2026: PIB release on five commissioned greenfield projects. [1]
• Status of 48 approved projects, 32 companies, and ₹4,709 crore invested. [2] The date of that release was not confirmed.

7. Prelims Hooks

• The scheme is administered by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. [1]
• Outlay is ₹6,940 crore, covering 41 products. [2]
• Scheme period is 2020-21 to 2029-30. [2]
• Only greenfield projects are eligible. [2]
• Penicillin G: Kakinada SEZ, 15,000 MT per annum, restored after about 30 years. [1]
• Potassium Clavulanate: India's first fermentation-based plant, at Nalagarh, Himachal Pradesh. [1]
• PAP is the starting material for Paracetamol. Meghmani's plant is at Dahej, Gujarat. [1]
• Atorvastatin API plant: Centrient, Nawanshahr, Punjab, 206 MT per annum. [1]
• Sulfadiazine: imports fell about 73% against the FY2019-20 baseline. [1]
• Telmisartan and Olmesartan are antihypertensive APIs. [1]
• Clavulanic Acid is a β-lactamase inhibitor. [1]
• 6-APA is made from Penicillin G. [1]

8. Why India Will Still Buy Chinese APIs After These Plants Open

• The plants are new, but the price gap is old
• About two-thirds of India's imports of bulk drugs and drug intermediates come from China [7].
• The government's own answer says these imports continue for economic reasons — APIs from China are about 35-40% cheaper than the same API made in India [7].

• So a buyer in India (a formulation company) can have a domestic Penicillin G plant next door and still import, because the imported drum costs less.

• Why Chinese APIs are cheaper is not a mystery, and none of it is fixed by a production incentive

• Fermentation plants (where a living micro-organism grows the drug, as with Penicillin G) run huge boilers and effluent treatment day and night. Power and effluent cost is the biggest part of the bill.
• The Katoch Committee saw this and asked for shared infrastructure — common Effluent Treatment Plants, captive power plants or assured State power, common testing and storage — inside large API parks run by a Special Purpose Vehicle (SPV) [10].

• A PLI payment rewards output after the fact. It does not lower the electricity tariff or the effluent bill that made the output costly in the first place.

• What this means for the exam answer — "import substitution achieved" is the wrong claim. The right claim is that India now has the option to make these molecules. Whether it uses that option depends on price.

9. What ₹2,720 Crore of Sales Means Against a ₹6,940 Crore Scheme

• Read the output number next to the scheme's size, not on its own
• Cumulative sales under the scheme reached ₹2,720 crore up to December 2025, including exports of ₹527.96 crore, and avoided imports worth ₹2,192.04 crore [8].
• The scheme's outlay is ₹6,940 crore over ten years [2].

• So roughly five years in, the total value of goods sold is still smaller than the money the government has set aside to pay out. That is normal for a scheme whose plants take years to build — but it means the "success" story is about capacity, not yet about scale.

• Ten of the 48 approved projects are still not running

• As of December 2025, 38 of the 48 approved projects were commissioned, covering 28 of the 33 subscribed products, and creating capacity of about 56,800 MT per year [8].

• The remaining projects are the test. The Department had to reopen applications for vacant slots under the bulk drugs PLI as late as March 2022 [12] — meaning some approved products found no taker at all.

• Avoided imports of ₹2,192 crore is a small dent — India's bulk drug imports are still two-thirds Chinese [7]. Import substitution has started; dependence has not ended.

10. The Cost Gap Outlives the Incentive

• The incentive is time-bound; the disadvantage is permanent
• Incentive rates were set higher for fermentation-based products (20%) than for chemically synthesised ones (10%) [9]. Government itself accepted that fermentation is the harder, costlier route.
• But PLI money is paid for a fixed number of years. After the last payment, the plant faces the same 35-40% price gap against China with no support [7].

• A fermentation plant cannot simply switch off and restart. If it becomes unviable, the capacity is lost again — exactly how India lost Penicillin G for about three decades in the first place [1].

• This is the fault line on which the earlier attempt already failed

• The Katoch Committee had recommended reviving public sector units to make critical drugs including penicillins [10]. That route did not restore supply.

• The lesson is that ownership was never the problem. Running cost was.

• So the real question for 2030 — not "did the plants get built", but "can they sell at a price an Indian formulation maker will pay once the incentive stops".

11. The Strongest Case For the Scheme, and Where It Holds

• The honest objection — if a domestic API costs 35-40% more [7], forcing India to make it raises the price of medicines for poor patients. Cheap imports are not a weakness; they are how India became the "pharmacy of the world". Spending ₹6,940 crore [2] to make expensive versions of cheap molecules looks like poor use of public money.
• Where that objection is right — it is right about cost. The extra cost is real, and somebody pays it: either the taxpayer through incentives, or the patient through price.
• Where it fails — it prices the molecule but not the risk.
• Two-thirds import concentration in one country [7] is not ordinary trade. One export curb, one port closure, one price spike, and India's antibiotic supply stops.
• Penicillin G is the starting point for 6-APA, which becomes amoxicillin and ampicillin [1] — the most widely used antibiotics in Indian primary care. A break here is not one shortage; it runs through the whole chain.

• The right way to state it: this is insurance, and insurance always costs more than going uninsured. The duty is to buy only as much as needed — which is why the scheme covers 41 identified critical products [2], not every API.

• The fair verdict — the case for domestic Penicillin G is strong. The case for keeping it alive after 2030 has not yet been made.

12. What Must Happen Next for These Plants to Survive

• Department of Pharmaceuticals: finish the Bulk Drug Parks, do not stop at the incentive
• The Bulk Drug Parks scheme was launched alongside the PLI for exactly this reason — to build common infrastructure for API making [11].
• The Katoch Committee's design is the template: common Effluent Treatment Plant, assured power, shared testing and storage, run by an SPV [10].

• This is the only lever that cuts the per-unit cost permanently. A park lowers the bill every year; an incentive lowers it only while it is paid.

• Department of Pharmaceuticals: track the ten uncommissioned projects by name

• 38 of 48 are running [8], and vacant slots had to be re-advertised once already [12].

• Publishing why a specific project stalled — land, environmental clearance, or the promoter walking away — is what turns a scheme report into a usable lesson.

• Government buyers: use purchase, not only subsidy

• Public health programmes buy antibiotics in bulk. A stated preference for APIs with high domestic value addition gives a guaranteed offtake.
• Two commissioned plants already report over 90% (Lyfius, Penicillin G) and over 80% (Centrient, Atorvastatin) domestic value addition [1] — the measure already exists and can be used as the buying condition.

13. Anchors for Answers

• Data: About two-thirds of India's bulk drug and drug intermediate imports come from China; Chinese APIs are roughly 35-40% cheaper than Indian ones [7]
• Data: ₹2,720 crore cumulative sales, ₹527.96 crore exports, ₹2,192.04 crore imports avoided, 38 of 48 projects commissioned, ~56,800 MT per annum capacity, up to December 2025 [8]
• Data: Incentive rate of 20% for fermentation-based products against 10% for chemically synthesised ones [9]
• Report/Committee: Katoch Committee — recommended mega API parks with common Effluent Treatment Plants, captive/assured power and shared utilities under an SPV, plus revival of PSUs for critical drugs including penicillins [10]
• Scheme: Bulk Drug Parks scheme, launched alongside the PLI, as the infrastructure-side answer to the running-cost problem [11]
• Scheme: PLI for Bulk Drugs — ₹6,940 crore, 41 critical products, FY2020-21 to FY2029-30, greenfield only [2]

14. Mains Relevance

• GS-III: Indian Economy, including industrial policy, manufacturing and the effects of liberalisation. GS-II: health and government policies and interventions.
• Plausible questions: 1. Critically examine how PLI schemes can reduce India's import dependence in strategic sectors, with reference to bulk drugs. 2. Discuss the role of backward integration in making pharmaceutical supply chains resilient. 3. Evaluate the significance of restoring domestic Penicillin G production for India's health security.

15. Related Topics to Study Next

• Bulk Drug Parks scheme: a complementary infrastructure-side measure.
• PLI for pharmaceuticals: the finished-formulation side.
• PLI architecture across sectors: design and outcomes.
• Antimicrobial resistance: the link to β-lactamase inhibitors.
• Pharmaceutical exports: India's role as "pharmacy of the world".
• Supply-chain resilience and China dependence: the strategic context.
• Essential Medicines / NLEM and price control: the affordability side.
• SEZs: Kakinada SEZ hosts the Penicillin G project. [1]

16. Common Errors / Trap Areas

• Confusing schemes: the bulk-drug PLI (₹6,940 crore, KSMs/DIs/APIs) is separate from the broader pharma PLI and the Bulk Drug Parks scheme.
• Confusing ministries: it is the Department of Pharmaceuticals under Chemicals and Fertilizers, not Health.
• Confusing greenfield with brownfield: only greenfield projects are covered. [2]
• Mixing KSM, DI and API: Penicillin G is a KSM, 6-APA is an intermediate, and amoxicillin is the end drug. [1]
• Confusing figures: outlay (₹6,940 crore) is not the same as maximum incentive payout (about ₹6,000 crore). [2]